Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published May 2013 | Supplemental Material
Journal Article Open

Allelic Exclusion and Peripheral Reconstitution by TCR Transgenic T Cells Arising From Transduced Human Hematopoietic Stem/Progenitor Cells

Abstract

Transduction and transplantation of human hematopoietic stem/progenitor cells (HSPC) with the genes for a T-cell receptor (TCR) that recognizes a tumor-associated antigen may lead to sustained long-term production of T cells expressing the TCR and confer specific antitumor activity. We evaluated this using a lentiviral vector (CCLc-MND-F5) carrying cDNA for a human TCR specific for an HLA-A*0201-restricted peptide of Melanoma Antigen Recognized by T cells (MART-1). CD34+ HSPC were transduced with the F5 TCR lentiviral vector or mock transduced and transplanted into neonatal NSG mice or NSG mice transgenic for human HLA-A*0201 (NSG-A2). Human CD8+ and CD4+ T cells expressing the human F5 TCR were present in the thymus, spleen, and peripheral blood after 4–5 months. Expression of human HLA-A*0201 in NSG-A2 recipient mice led to significantly increased numbers of human CD8+ and CD4+ T cells expressing the F5 TCR, compared with control NSG recipients. Transduction of the human CD34+ HSPC by the F5 TCR transgene caused a high degree of allelic exclusion, potently suppressing rearrangement of endogenous human TCR-β genes during thymopoiesis. In summary, we demonstrated the feasibility of engineering human HSPC to express a tumor-specific TCR to serve as a long-term source of tumor-targeted mature T cells for immunotherapy of melanoma.

Additional Information

© 2013 The American Society of Gene & Cell Therapy. Received 2 November 2012; accepted 27 December 2012; advance online publication 5 February 2013. This work was funded by the National Institutes of Health (PO1 CA132681, D Baltimore, PI), the Samuel Waxman Foundation (J. Economou, PI), the California Institute for Regenerative Medicine New Faculty Award 2 (RN2-00902-A. Ribas, PI), and the W.M. Keck Foundation (J Economou, PI) with support from the University of California, Los Angeles (UCLA), Eli & Edythe Broad Center of Regenerative Medicine & Stem Cell Research and the UCLA Jonsson Comprehensive Cancer Center. O.N.W. is an Investigator of the Howard Hughes Medical Institute. The services of the UCLA Immunogenetics Center, the Broad Stem Cell Research Center Flow Cytometry Core and the UCLA CFAR (AI028697)/JCCC Virology Core were used for these studies. We thank the nurses and Obstetric Residents at the UCLA Ronald Reagan Medical Center Labor and Delivery Center for obtaining umbilical cord blood units for this research. The other authors declared no conflict of interest.

Attached Files

Supplemental Material - mt20138x1.pdf

Files

mt20138x1.pdf
Files (447.8 kB)
Name Size Download all
md5:9b7f8adf019caaf2c5bbc40b62dae8f5
447.8 kB Preview Download

Additional details

Created:
August 19, 2023
Modified:
October 24, 2023